SEC Info - Novartis Bioventures Ltd., et al. - ‘SC 13G/A’ on 2/1/21 re: Adicet Bio, Inc.

SEC Info℠

Home

Help

Please Sign In

Novartis Bioventures Ltd., et al. – ‘SC 13G/A’ on 2/1/21 re: Adicet Bio, Inc. – ‘EX-4’

On: Monday, 2/1/21, at 8:34am ET · Accession #: 1104659-21-9738 · File #: 5-90283

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/01/21  Novartis Bioventures Ltd.         SC 13G/A               2:85K  Adicet Bio, Inc.                  Toppan Merrill/FA
          Novartis AG
          Novartis Institutes for Biomedical Research, Inc.

Amendment to Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Sch. 13G — WA’68
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G/A    Amendment to Statement of Acquisition of            HTML     40K 
                Beneficial Ownership by a "Passive" Investor                     
 2: EX-4        Instrument Defining the Rights of Security Holders  HTML      9K

‘EX-4’ — Instrument Defining the Rights of Security Holders

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EXHIBIT 4

Joint Filing Agreement

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Adicet Bio, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided that no party is responsible for the completeness or accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of February 1, 2021.

		Novartis Bioventures Ltd.

		/s/ *Bart Dzikowski*
		Name: Bart Dzikowski
		Title: Secretary of the Board

		/s/ *Beat Steffen*
		Name: Beat Steffen
		Title: Authorized Signatory

		Novartis Institutes for
		BioMedical Research, Inc.

		/s/ *Scott A. Brown*
		Name: Scott A. Brown
		Title: General Counsel and Chief Administrative Officer

		Novartis AG

		/s/ *Bart Dzikowski*
		Name: Bart Dzikowski
		Title: Authorized Signatory

		/s/ *Beat Steffen*
		Name: Beat Steffen
		Title: Authorized Signatory

Dates Referenced Herein and Documents Incorporated by Reference

This ‘SC 13G/A’ Filing	Date	Other Filings

Filed on:	2/1/21	SC 13G, SC 13G/A
		List all Filings

↑Top

Filing Submission 0001104659-21-009738 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)